Digital Indocyanine Green Videoangiography of Central Serous Chorioretinopathy

Guyer, David R.; La, Yannuzzi; Slakter, Jason S.; Sorenson, John A.; Ho, Alexander; Orlock, Dennis A.

doi:10.1097/00006982-199515010-00032

Cited by 107 publications

(143 citation statements)

References 0 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…The etiology and pathophysiology of CSCR is varied but ultimately leads to widespread hyperdynamic and hyperpermeable choroidal circulation with localized areas of choroidal nonperfusion. 1,2 CSCR is usually self-limiting with good recovery of visual function. However, 33-50% of cases can have recurrences with longstanding areas of neurosensory detachment leading to permanent visual impairment.…”

Section: Introductionmentioning

confidence: 99%

Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome

Yadav

Jayadev

Mohan

et al. 2015

Eye

111

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome

Yadav

Jayadev

Mohan

et al. 2015

Eye

111

View full text Add to dashboard Cite

“…[1][2][3][4] The disorder is usually self-limited, although some patients are left with permanent visual impairment because of pigment epithelium and photoreceptor damage, especially in chronic CSC. 1,2,5,6 Hypotheses include abnormal alterations at the retinal pigment epithelium (RPE) level 2,3,7 and choroidal vascular hyperpermeability, as demonstrated on indocyanine green angiography. [7][8][9] CSC has a high spontaneous remission rate, but there is evidence of the benefit of early treatment.…”

Section: Introductionmentioning

confidence: 99%

“…1,2,5,6 Hypotheses include abnormal alterations at the retinal pigment epithelium (RPE) level 2,3,7 and choroidal vascular hyperpermeability, as demonstrated on indocyanine green angiography. [7][8][9] CSC has a high spontaneous remission rate, but there is evidence of the benefit of early treatment. [10][11][12] CSC with single, extrafoveal leaking point can be treated using focal photocoagulation to shorten the duration of symptoms without altering the final visual outcomes and the recurrent rate.…”

Section: Introductionmentioning

confidence: 99%

Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review

Younghae

et al. 2013

Eye

View full text Add to dashboard Cite

Purpose To review and evaluate the effects of intravitreal bevacizumab injection (IVB) in centralserous chorioretinopathy (CSC) by meta-analysis. Patients and methods Clinical controlled studies that evaluated the effect of IVB in CSC were identified through systematic searches of Embase, PubMed, and the Cochrane Central Register of Controlled Trials. Data on the bestcorrected visual acuity (BCVA) in logMAR and central macular thickness (CMT) in mm at baseline and 6 months after IVB were extracted and compared with those treated by simple observation.Results Four clinical controlled studies were included in the meta-analysis. The IVB injection group achieved better BCVA at a follow-up of 6 months. However, the analysis showed that there were no significant differences of BCVA at 6 months after injection between IVB group and the observation group ( À 0.02 logMAR, 95% CI À 0.14 to 0.11, P ¼ 0.80). The analysis of the reduction in CMT revealed that the difference between groups was not statistically significant ( À 8.37 lm, 95% CI À 97.26 to 80.52, P ¼ 0.85). No report assessed severe complications or side effects of IVB in patients with CSC. Conclusions Meta-analysis failed to verify the positive effect of IVB in CSC based on the epidemiological literature published to date.

show abstract

“…[2][3][4] The introduction of indocyanine green angiography (ICGA) supported the suggestion that choroidal vascular abnormality might be responsible for this condition. 5,6 Hyperpermeability of the choroid shown on ICGA, a characteristic feature of CSC, may induce a functional loss of retinal pigment epithelial cells and abnormal egress of fluid under the retina.…”

Section: Introductionmentioning

confidence: 99%

Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy

Kang

Bai

2011

Eye

127

101

View full text Add to dashboard Cite

Objective To assess the change in the choroidal thickness of the unaffected eyes in patients with unilateral central serous chorioretinopathy (CSC). Methods Thirty eyes with unilateral idiopathic CSC and 30 age-matched normal eyes were included in this study. Choroidal thickness was evaluated from images obtained by enhanced depth image optical coherence tomography. The choroidal thicknesses of the affected eyes, unaffected eyes, and normal eyes were analyzed. Choroidal vascular dilation and hyperpermeability on indocyanine green angiography (ICGA) were analyzed and correlated with the changes in choroidal thickness. Results The mean choroidal thicknesses of the affected eyes, unaffected fellow eyes, and normal individuals were 445.58 ± 100.25, 378.35±117.44, and 266.80±55.45 lm, respectively. Compared with normal eyes, subfoveal choroidal thickness was increased significantly in the eyes with active CSC and in the unaffected fellow eyes (Po0.001 in both groups). The choroidal thickness was significantly greater in the eyes with active CSC than in the unaffected fellow eyes (P ¼ 0.003). ICGA revealed choroidal vascular hyperpermeability in 28 (93.3%) eyes with CSC and in 23 (73.3%) unaffected fellow eyes. Choroidal vascular dilation was detected in 21 (70.0%) eyes with CSC and in 18 (60.0%) unaffected fellow eyes. Conclusion Increased choroidal thickness in patients with unilateral CSC was noted not only in the affected eyes, but also in the unaffected fellow eyes. The results of this study suggest that CSC might be an essentially bilateral disorder.

show abstract

Digital Indocyanine Green Videoangiography of Central Serous Chorioretinopathy

Cited by 107 publications

References 0 publications

Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome

Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome

Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review

Choroidal thickness in both eyes of patients with unilaterally active central serous chorioretinopathy

Contact Info

Product

Resources

About